Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 99kWORD 16k
5 July 2017
E-004576-17
Question for written answer E-004576-17
to the Commission
Rule 130
Karol Karski (ECR)

 Subject:  Antimicrobial resistance
 Answer in writing 

Given that the number of deaths caused by antimicrobial resistance keeps increasing and the Commission’s preliminary forecasts reveal that by 2050 that number will have exceeded the number of cancer-related deaths, the Commission has adopted a new action plan on this issue. The plan is based on the ‘one health’ approach and it concerns both humans and animals. Microbial resistance causes 25 000 deaths each year, whereas economic losses throughout the Union total about EUR 1.5 billion.

1. Has the Commission developed EU guidelines on the prudent use of antimicrobial agents in humans?2. Will the EU continue its international initiatives, such as the partnership between Europe and developing countries on clinical trials and the common programming initiative?3. Will the Member States create a global system of more integrated and advanced research into antimicrobial resistance?

Original language of question: PL 
Legal notice